Trials / Completed
CompletedNCT02921035
Non-interventional Study to Assess Adherence to Treatment for Patients With RMS (MAIN-MS)
A Multicenter, Prospective, Non-interventional Study to Assess Adherence to Treatment for patIeNts With RMS Who Are Prescribed Subcutaneous (sc) Interferon Beta-1a (MAIN-MS)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 594 (actual)
- Sponsor
- Merck KGaA, Darmstadt, Germany · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
This is an open label, non randomized, uncontrolled, multicenter, single arm observational study. In this study, the enrolled subjects will be treated with Rebif human serum albumin (HSA)-free formulation (with or without RebiSmart) 44 microgram (mcg), subcutaneous (sc), thrice in a week (tiw) for 24 months.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rebif (Interferon beta-1a) | Rebif will be administered at a dose of 44 mcg, sc, tiw. |
Timeline
- Start date
- 2016-06-30
- Primary completion
- 2020-07-27
- Completion
- 2020-07-27
- First posted
- 2016-09-30
- Last updated
- 2022-04-04
Locations
41 sites across 13 countries: Algeria, Argentina, Bahrain, Bulgaria, Egypt, Hungary, Iran, Kuwait, Lebanon, Morocco, Poland, Saudi Arabia, South Korea
Source: ClinicalTrials.gov record NCT02921035. Inclusion in this directory is not an endorsement.